GOVX GeoVax Labs, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 832489 · Fiscal year ends 12/31
Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-84.8%
TTM net income YoY12.8%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-2,523.4%
Net margin-2,507.3%
FCF margin-2,236.0%
EBITDA margin-2,515.9%
Returns
ROE-509.3%
ROA-309.3%
ROIC (approx.)—
Asset turnover0.12x
Leverage & solvency
Liabilities / assets83.4%
Debt / equity0.00x
Current ratio1.06x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.89x
Accruals ratio-33.6%
Payout ratio—
Capex / revenue1.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $852,282 | $1.64M | $864,415 |
| R&D expense | $2.82M | $3.11M | $3.90M | $2.99M | $5.04M | $4.73M | $5.35M | $7.61M |
| SG&A expense | $1.35M | $1.33M | $1.37M | $1.45M | $1.33M | $1.54M | $1.69M | $1.60M |
| Operating income | -$4.17M | -$4.44M | -$5.27M | -$4.44M | -$6.37M | -$5.42M | -$5.41M | -$8.34M |
| Interest expense | — | — | — | $0 | $0 | $0 | — | $0 |
| Income tax | $0 | $0 | $0 | — | $0 | $0 | $0 | — |
| Net income | -$4.16M | -$4.43M | -$5.26M | -$4.42M | -$6.32M | -$5.37M | -$5.36M | -$8.26M |
| EBITDA | -$4.17M | -$4.43M | -$5.26M | -$4.42M | -$6.36M | -$5.40M | -$5.39M | -$8.32M |
| EPS (basic) | -10.56 | -0.97 | -2.62 | — | -150.68 | -8.74 | -11.20 | — |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $2.15M | $3.14M | $1.27M | $3.09M | $5.01M | $3.09M | $7.44M | $5.51M |
| Receivables | — | — | — | $0 | $0 | $532,771 | $1.50M | $659,409 |
| Current assets | $3.11M | $4.18M | $2.43M | $5.31M | $6.52M | $5.14M | $10.61M | $7.93M |
| PP&E, net | $10,551 | $84,678 | $96,754 | $108,830 | $127,060 | $143,862 | $149,947 | $149,974 |
| Total assets | $3.42M | $4.64M | $2.98M | $6.34M | $6.73M | $5.35M | $10.83M | $8.16M |
| Current liabilities | $2.14M | $2.71M | $2.29M | $1.94M | $1.82M | $2.53M | $2.94M | $3.11M |
| Total liabilities | $2.28M | $2.88M | $2.49M | $2.52M | $1.82M | $2.53M | $2.94M | $3.11M |
| Shareholders' equity | $1.15M | $1.76M | $493,770 | $3.83M | $4.91M | $2.82M | $7.90M | $5.05M |
| Shares outstanding | 420,953 | 7.37M | 2.82M | 72,173 | 29.71M | 15.92M | 13.84M | 421,475 |
| Cash flow statement | ||||||||
| Operating cash flow | -$4.34M | -$3.66M | -$3.54M | -$4.96M | -$6.21M | -$4.33M | -$5.97M | -$7.75M |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 | $10,718 | $16,894 | $0 |
| Free cash flow | -$4.34M | -$3.66M | -$3.54M | -$4.96M | -$6.21M | -$4.35M | -$5.98M | -$7.75M |
| Investing cash flow | $7,000 | $0 | $0 | $0 | $0 | -$10,718 | -$16,894 | $0 |
| Financing cash flow | $3.34M | $5.53M | $1.72M | $3.04M | $8.13M | $209 | $7.91M | $4.67M |
| Depreciation & amortization | $8,542 | $12,076 | $12,076 | $18,230 | $16,802 | $16,803 | $16,921 | $21,641 |
| Stock-based compensation | $221,639 | $163,746 | $219,317 | $252,124 | $277,546 | $292,740 | $292,744 | $139,345 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.